PFE just may be poised to jump in when the Nestle deal closes and the last of this years warrants expire in July, this summer. No news on HSS, Neuron Systems, or phase 1- 2 of the Pfizer dose study. I think by fall we'll see some real activity with the outstanding shares in this price range. Not to mention the rev's from ALIM marketing partnership deal which should happen in the fall as well. It's not easy to own this stock with it's high beta characteristics.